Sino Biopharmaceutical Limited (FRA:SMZ1)

Market Cap	13.85B
Revenue (ttm)	3.63B
Net Income (ttm)	460.14M
Shares Out	n/a
EPS (ttm)	0.03
PE Ratio	30.11
Forward PE	24.57
Dividend	0.01 (1.27%)
Ex-Dividend Date	Aug 29, 2025

Volume	n/a
Average Volume	5,897
Open	0.7594
Previous Close	0.7830
Day's Range	0.7594 - 0.7800
52-Week Range	0.3392 - 0.9926
Beta	n/a
RSI	45.41
Earnings Date	Nov 30, 2025

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 24,379
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SMZ1

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY